Table 2.
Incremental cost-effectiveness ratios of screening strategies at age 40 yr (compared to no screening strategy unless stated)
| US$/QALY |
Base-case |
Best-case1 |
Worst-case1 |
|||
| Serology | UBT | Serology | UBT | Serology | UBT | |
| ICER per life year saved | 16 166 | 38 792 | Dominant | Dominant | 389 728 | 640 000 |
| 477 0792 | Dominant2 | 5 645 4492 | ||||
| ICER per QALY gained | 13 571 | 32 525 | Dominant | Dominant | 324 773 | 560 000 |
| 390 3372 | Dominant2 | Dominated2 | ||||
ICER: Incremental cost-effectiveness ratio; QALY: Quality-adjusted life year; UBT: 13C-Urea breath test.
1
Variables modified in best and worst-case analyses were, gastric cancer risk reduction by eradication (100% and 10%, respectively), relative risk (12 and 2), cost of annual gastric cancer treatment ($59 000 and $328), cost of the serology screening ($10 and $50), cost of the UBT ($60 and $100), and annual discount rate (0% and 7%);
2
The ICER was calculated by comparing the UBT with the serology screening.